mAbxience | CDMO


Independent CDMO platform with +40 years of experience within Insud Pharma Group, with a complete range of analytical and development processes to provide clients with end-to-end solution.

mAbxience CDMO business offers a complete services comprising analytical and development capabilities, from small R&D and clinical batches to full commercial production:

  • Process & analytical development infrastructure from process development to optimization and scale up.
  • Robust processes following cGMP manufacturing guidelines.
  • Constantly expanding global capacities and capabilities with flexibility provided by 3L to 4,000L single-use bioreactors.
  • Additionally investing in expanded capacity to build out the CDMO platform and better serve biopharma partners.
  • Internal and external Technology Transfer expertise.
  • Examples of product offerings include monoclonal antibodies, cytokines, chimeric proteins, recombinant hormones, adenoviral or baculovirus vaccines, and other glycosylated recombinant proteins.

Pre-clinical and clinical stage CDMO activities constitute the greatest relevance in the market, and new modalities are growing at a high pace.